Latimer, Nicholas R
Dewdney, Alice
Campioni, Marco
Funding for this research was provided by:
Yorkshire Cancer Research (S406NL)
Article History
Received: 11 April 2023
Accepted: 2 January 2024
First Online: 22 January 2024
Declarations
:
: For studies 20020408 (NCT00113763) and 20030194 (NCT00113776) study protocols were approved by the independent ethics committee at participating study centers, and all patients provided written, informed consent before any study-related procedures were performed. A list of the independent ethics committees that approved studies 20020408 and 20030194 is provided in Appendix InternalRef removed. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: NL reports grants from Yorkshire Cancer Research, during the conduct of the study; grants from Bristol-Myers Squibb, grants from Merck, Sharpe and Dohme, outside the submitted work. MC reports to be employed by Amgen (Europe) GmbH, Rotkreuz, Switzerland, during the conduct of the study and to own Amgen stocks and options. AD has nothing to disclose.